-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in US stocks | Ventyx Biosciences (VTYX.US) surged more than 37%, and LLY.US (LLY.US) is close to reaching a more than $1 billion acquisition deal

Zhitongcaijing·01/07/2026 14:57:07
Listen to the news

The Zhitong Finance App learned that on Wednesday, Ventyx Biosciences (VTYX.US) stock price skyrocketed. As of press release, the stock had risen more than 37% to $13.79. According to reports, LLY.US (LLY.US) is close to reaching a deal to acquire the company for more than 1 billion US dollars. If the deal is reached, Eli Lilly will add inflammatory bowel disease-related drugs to the research pipeline, including treatment programs for Crohn's disease and ulcerative colitis, while also supplementing R&D assets in diseases such as Parkinson's disease.

Furthermore, an experimental drug from Ventyx is currently in the mid-clinical phase to treat an obesity-related cardiovascular disease and is regarded as an important potential item in its pipeline.